Skip to main content
SpringerLink
Log in

Hypothesis: How Licensed Vaccines Confer Protective Immunity

  • Chapter
Novel Strategies in the Design and Production of Vaccines

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 397))

Abstract

By examining experience with evaluation of licensed vaccines we theorize that a critical level of serum IgG confers protection against infectious diseases by killing or inactivating the inoculum. We found that efficacy is reliably predicted by measurement of serum antibodies elicited by vaccines, that serum IgG antibodies alone account for the protection conferred by passive immunization, that vaccine-induced “herd” immunity is best explained by inactivation of the inoculum on epithelial surfaces by serum antibodies and that serum antibodies induced by active immunization will neither treat disease symptoms nor eliminate the pathogen. If valid, this theory should facilitate research because knowledge of the pathogenesis of the disease symptoms may not be essential for vaccine development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ad Hoc Group for the study of pertussis vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet i:955–960.

    Google Scholar 

  2. Alexander H.E. Experimental basis for treatment of Haemophilus influenzae infections. Amer. J. Dis. Child. 1943:66:160–71.

    CAS  Google Scholar 

  3. Andersson M., Carlin N, Leontein K, Lindquist U, Slettengren K. Structural studies of the O-antigenic polysaccharide of Escherichia coli O86, which possess blood-group B activity. Carbohydr. Res. 1989:185:211–23.

    Article  PubMed  CAS  Google Scholar 

  4. Anderson P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM 197. Infect. Immun. 1983:39:233–8.

    PubMed  CAS  Google Scholar 

  5. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev. Infect. Dis. Suppl: 1981:S1-S17

    Google Scholar 

  6. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency and susceptibility to neonatal group B streptococcal infection. N. Eng. J. Med. 294:753–756.

    Google Scholar 

  7. Batty I, Bullen JJ. The permeability of the sheep and rabbit intestinal wall to antitoxin present in the circulation. J. Path. Bact. 1961:81:447–58.

    Article  PubMed  CAS  Google Scholar 

  8. Beasley RP, Hwang L-Y, Steven CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983:3:135–41.

    Article  PubMed  CAS  Google Scholar 

  9. Bellamy JEC, Ole Nielsen N. Immune-mediated emigration of neutrophils into the lumen of the small intestine. 1974:9:615–19.

    CAS  Google Scholar 

  10. Bellanti JA. Biologic significance of the secretory yA immunoglobulins. Pediatr. 1975:48:715–29.

    Google Scholar 

  11. Benenson AS. Review of experience with whole-cell and somatic antigen vaccines. Proceedings of the 12th Joint Conference of US Japan Cooperative Medical Sciences Program, Cholera Panel, Sapporo. 1976:228-42.

    Google Scholar 

  12. Black SB, Shinefield HR, and the Kaiser Permanente Vaccine Study Group. Pediatr. Infect. Dis. J. 1992:11:610–13.

    PubMed  CAS  Google Scholar 

  13. Blaser MJ. Newman LS. A review of human salmonellosis: Infective dose. Rev. Infect. Dis. 1982:4:1096–106.

    Article  PubMed  CAS  Google Scholar 

  14. Böttiger M. Long-term immunity following vaccination with killed poliovirus vaccine in Sweden, a country with no circulating virus. Rev. Infect. Dis. 1984:6:S548–S51.

    Article  PubMed  Google Scholar 

  15. Bouvet JP, Bélec L, René Pirès, Pilot J. Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination. Infect. Immun. 1994:62:3957–61

    PubMed  CAS  Google Scholar 

  16. Bruss JB, Siber G. Treatment of severe pertussis with intravenous pertussis immune globulin. Abstract ICCAAC 103761.1993.

    Google Scholar 

  17. Bruton OC. Agammaglobulinemia. Pediatr. 1952:9:727–8.

    Google Scholar 

  18. Carlin NIA, Svenson SB, Lindberg AA. Role of monoclonal 0-antigen antibody epitope specificity and isotype in protection against experimental mouse typhoid. Microbiol. Path. 1987:2:171–183130.

    Article  CAS  Google Scholar 

  19. Centers for Disease Control. General Recommendations on Immunization. MMWR. 1994:43:RR–1.

    Google Scholar 

  20. Centers for Disease Control. Inactivated Japanese Encephalitis Virus Vaccine. MMWR, 1993:42:RR–1.

    Google Scholar 

  21. Centers for Disease Control. Pertussis vaccination: Acellular pertussis vaccine for reinforcing and booster use-Supplementary ACIP Statement. MMWR. 1992:41:1–10.

    Google Scholar 

  22. Centers for Disease Control. Rubella Prevention. MMWR, 1981:3037–47

    Google Scholar 

  23. Chanock RM, Crowe JE Jr, Murphy BR, Burton DR. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: Potential usefulness in prevention and.or treatment of major human viral diseases. Infect. Agents Dis. 1993:2:118–31.

    PubMed  CAS  Google Scholar 

  24. Chodriker WB, Tornasi TB Jr. Gamma globulins: quantitative relationship in human sera and non-vascular fluids. Science 1963:142:1080–81.

    Article  Google Scholar 

  25. Chu CY, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immun. 1983:40:245–56.

    PubMed  CAS  Google Scholar 

  26. Clemens JD, Sack DA, Chakraborty J. et al. Field trial of oral cholera vaccines in Bangladesh: Evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. Vaccine 1990:8:469–72.

    Article  PubMed  CAS  Google Scholar 

  27. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from a three-year follow-up. Lancet 1990:335:270–73.

    Article  PubMed  CAS  Google Scholar 

  28. Cohen D, Ashkenazi S, Green M. et al. Safety and immunogenicity of Shigella flexneri 2a and Shigella sonnei conjugate vaccines: preliminary efficacy of the S. sonnei conjugate in Israeli soldiers, submitted for publication. 1994.

    Google Scholar 

  29. Cohen D, Green MS, Block C., Slepon R, Ofek I. A prospective study on the association between serum antibodies to lipopolysaccharide and attack rate of shigellosis. J. Clin. Microbiol. 1991:29:386–9.

    PubMed  CAS  Google Scholar 

  30. Conley AJ, Gorny MK, Kessler JA II. et al. Neutralization of pimrary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 1994:68:6994–7000.

    PubMed  CAS  Google Scholar 

  31. Douglas RM, Hansman D, Miles HB, Paton JC. Pneumococcal carriage and type-specific antibody. Failure of a 14-valent vaccine to reduce carriage in healthy children. Am. J. Dis. Child. 1986:140:1183–5.

    PubMed  CAS  Google Scholar 

  32. DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 1989:159:1126–28.

    Article  PubMed  CAS  Google Scholar 

  33. Eibl MM, Cairns L, Rosen FS. Safety and efficacy of a monomeric, functionally intact intravenous IgG preparation in patients with primary immunodeficiency syndromes. Clin. Imunol. Immunopathol. 1994:31:151–69.

    Article  Google Scholar 

  34. Faden H, Modlin JF, Thomas ML, McBean AM, Ferdon MB, Ogra P.L. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated poliovirus vaccines in childhood: Systemic and local immune responses. J. Infect. Dis. 1990:162:1291–97.

    Article  PubMed  CAS  Google Scholar 

  35. Ferreccio C., Prado V, Ojeda A, Cayyazo M., Abrego P, Guers L, Levine MM. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Amer. J. Epid. 1991:134:614–27.

    CAS  Google Scholar 

  36. Fine PEM, Clarkson J. Measles in England and Wales III: Assessing published predictions of the impact of vaccination on incidence. Int. J. Epidemiol. 1983:12:332–39.

    Article  PubMed  CAS  Google Scholar 

  37. Floyd TM, Higgins AR, Kader MA. Studies in shigellosis. V. The relationship of age to the incidence of Shigella infections in Egyptian children, with special reference to shigellosis in the newborn and in infants in the first six months of life. Amer. J. Trop. Med. 1956:5:119–30.

    PubMed  CAS  Google Scholar 

  38. Fothergill LD, Wright J. Influenzai meningitis: relation of age incidence to the bactericidal power of blood against the causal organism. J. Immunol. 1993:24:273–84.

    Google Scholar 

  39. Fulginiti VA, Eller JJ, Donnei AW, Kempe CH. Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated virus vaccines. JAMA. 1967:202:1075.

    Article  PubMed  CAS  Google Scholar 

  40. Gaines S, Currie JA, Tully JG. Production of incomplete Vi antibody in man by typhoid vaccine. Amer. J. Epid. 1965:81:350–5.

    CAS  Google Scholar 

  41. Gershon A, Steinberg SP, The National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Live attenuated varicella vaccine: Protection in healthy adults compared with leukemic children. J. Infect. Dis. 1990:161:661–66.

    Article  PubMed  CAS  Google Scholar 

  42. Glezen WP, Lamb GA, Beiden EA, Chin TDY. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am. J. Epidemiol. 1968:83:224–37.

    Google Scholar 

  43. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 1969:129:1307–26

    Article  PubMed  CAS  Google Scholar 

  44. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J. Exp. Med. 1969:129:1385–95.

    Article  PubMed  CAS  Google Scholar 

  45. Granstrom M., Olinder-Nielsen AM, Holmbad P, Marks A, Hanngren K. Specific immunoglobulin for treatment of whooping cough. Lancet. 1991:33:1230–2.

    Article  Google Scholar 

  46. Gren KY, Taniguchi K, Mackow ER, Kapikian AZ. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J. Infect. Dis. 1990:161:667–79.

    Article  Google Scholar 

  47. Groothuis JR, Simoes EAF, Levin MJ. et al. Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High Risk Infants and Young Children. N. Engl. J. Med. 1993:329:1524–1527.

    Article  PubMed  CAS  Google Scholar 

  48. Guirgis N, Schneerson R, Bax A, Egan W, Robbins JB, Shiloach J, Ørskov I, Ørskov F. Escherichia coli K51 and K93 capsular polysaccharides cross-reactive with Group A meningococcal polysaccharide. J. Exp. Med. 1985:162:1837–51.

    Article  Google Scholar 

  49. Gupta RK, Robbins JB, Szu SC. Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide prepared by treatment with acetic acid or hydrazine and bound to tetanus toxoid by two synthetic schemes. Infect. Immun. in press. 1995.

    Google Scholar 

  50. Hambleton P, Turnbull RCB. Anthrax vaccine development: a continuing story. In Bacterial Vaccines, Eds F.A. Liss, Inc. New York, NY 1990:105–22

    Google Scholar 

  51. Isacson J, Trollfors B, Taranger J, MacDowell I, Johansson J, Lagergård T, Robbins JB. Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants. Pediatr. Infect. Dis. 1993:13:22–7.

    Google Scholar 

  52. Janeway CA, Rosen FS, Merler E, Alper CA. The gamma globulins. Little, Brown & Co., Boston. 1967.

    Google Scholar 

  53. Kampelbacher EH. On antigenic 0-relationships between the Groups Salmonella, Arizona, Escherichia and Shigella, Antonie van Leeuwenhoek J. Micro. Serol. 1984:25:289–324.

    Google Scholar 

  54. Katz MA, Landesman SH, Schiffman G. A comparison of antibody concentration measured by mouse protection assay and radioimmunoassay in sera from patients at high risk of developing pneumococcal disease. Mol. Immunol. 1984:21:1061–65.

    Article  PubMed  CAS  Google Scholar 

  55. Konadu E, Robbins JB, Shiloach J, Bryla DA, Szu SC. Preparation, characterization and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect. Immun. 1994:62:5048–54.

    PubMed  CAS  Google Scholar 

  56. Krugman S, Giles JP, Friedman H, Stone S. Studies on immunity to measles. J. Pediatr. 1965:66:471–88.

    Article  PubMed  CAS  Google Scholar 

  57. Levine MM, Ferreccio C., Black RE, Germanier R. Chilean Typhoid Committee. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet, 1987:i: 1049–52.

    Article  Google Scholar 

  58. Levine MM. Immunity to cholera as evaluated in volunteers. Cholera and Related Diarrheas. 43rd Nobel Symposium. Stockholm 1978. Karger, Basel. Eds. O. Ouchterlony and J. Holmgren. 1980:195-203.

    Google Scholar 

  59. Levine MM, Tacket CO. Recombinant live cholera vaccines. In Vibrio cholerae and Cholera. Molecular to Global Perspectives. Eds. I.K. Wachsmuth, P.A. Blake, Orjan Olsvik. American Society for Microbiology, Washington, DC. 1994:395–414

    Google Scholar 

  60. Lindberg AA, Haeggman S, Karlsson K, Dac Cam P, Du Trach D. The humoral antibody response to Shigella dysenteriae type 1 as determined by ELISA. Bull. W.H.O. 1984:62:597–606.

    PubMed  CAS  Google Scholar 

  61. MacLeod CM, Hodges RG, Heidelberger M., Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 1945:82:445–65.

    Article  Google Scholar 

  62. Mäkela PH, Herva E, Sibakov M., Henrichsen J, Luotonen J, Leinonen M., Timonen M., Koskela M., Pukander J, Gronroos P, Pontynen S, Karma P. Pneumococcal vaccine and otitis media. Lancet 1980:ii:547–51.

    Article  Google Scholar 

  63. Meade BD, Kind PD, Manclark CR. Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation. Infect. Immun. 1984:46:733–39.

    PubMed  CAS  Google Scholar 

  64. Mosley WH. The role of immunity in cholera: A review of epidemiology and serological studies. Tex. Rep. Biol. Med. 1969:27:227–41.

    Google Scholar 

  65. Mosley WH, Woodward WE, Aziz KMA, Rahman ASMM, Chowdhury AKMA, Ahmed A, Feely JC. The 1968–1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J. Infect. Dis. 1970:121:S1–S9.

    Article  Google Scholar 

  66. Moxon R, Murphy PA. Haemophilus influenzae bacteremia and meningitis resulting from the survival of a single organism. Proc Natl Acad Sci USA. 1978:75:1534–6.

    Article  PubMed  CAS  Google Scholar 

  67. Neoh SH, Rowley D. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J. Infect. Dis. 1970:121:505–13.

    Article  PubMed  CAS  Google Scholar 

  68. Norrby E, Penttiten K. Differences in antibody to the surface components of measles after immunization with formalin-inactivated and live virus vaccines. J. Infect. Dis. 1978:138:672–80.

    Article  PubMed  CAS  Google Scholar 

  69. Ogra PL, Karson DT, Righthand R, MacGillivray M. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N. Eng. J. Med. 1968:279:883–900.

    Article  Google Scholar 

  70. Orskov I, Orskov F, Jann B, Jann K. et al. Serology, chemistry, and genetics of 0 and K antigens in Escherichia coli. Bact. Rev. 1977:41:667–710.

    PubMed  CAS  Google Scholar 

  71. Pappenheimer AM Jr. Diphtheria. In Bacterial Vaccines. Ed. Rene Germanier. Academic Press, NY, 1984:1–32.

    Chapter  Google Scholar 

  72. Pappenheimer AM, Murphy JR. Studies on the molecular epidemiology of diphtheria. Lancet. 1983:2:923–25.

    Article  PubMed  CAS  Google Scholar 

  73. Peltola H, Mäkelä PH, Elo O, Pettay O, Renkonen OV, Sivonen A. Vaccination against meningococcal Group A disease in Finland 194–75. Scand. J. Infect. Dis. 1976:8:169–74.

    PubMed  CAS  Google Scholar 

  74. Pierce NF, Reynolds HY. Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization. J. Immunol. 1974: 113:1017–23.

    PubMed  CAS  Google Scholar 

  75. Pittman M. Pertussis toxin: The cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev. Infect. Dis. 1979:1:401–412

    Article  CAS  Google Scholar 

  76. Prince GA, Horswood RK, Chanock RM. et al. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol. 1985:55:517–20.

    PubMed  CAS  Google Scholar 

  77. Provost PJ, Hilleman MR. Propogation of human hepatitis A virus in cell culture in vitro Proc Soc Exp Biol. Med. 1978:160:213–21.

    Google Scholar 

  78. 1994 Redbook. Report of the Committee on Infectious Diseases. 1994. 23rd Edition, American Academy of Pediatrics, Rabies. 1994:383-95.

    Google Scholar 

  79. Redbook. Report of the Committee on Infectious Diseases. 1994. 23rd Ed, American Academy of Pediatrics, Tetanus, 1994:458-63.

    Google Scholar 

  80. Reynolds H, Thompson RE. Pulmonary host defenses. I. Analysis of protein and lipids in bronchial secretions and antibody responses after vaccination with Pseudomonas aeruginosa, J. Immunol. 1973:111:358–68.

    PubMed  CAS  Google Scholar 

  81. Robbins JB, Chu CY, Schneerson R. Hypothesis for vaccine development: Protective immunity to enteric diseases caused by nontyphoidal Salmonellae and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 1992:15:346–361

    Article  PubMed  CAS  Google Scholar 

  82. Robbins JB, Parke JC, Schneerson R, Whisnant JK. Quantitative measurement of “natural” and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediat. Res. 1973:7:103–10.

    Article  PubMed  CAS  Google Scholar 

  83. Robbins JB, Pittman M., Trollfors B, Lagergård TA, Taranger J, Schneerson R. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr. Infect. Dis. 1993:12:795–807.

    Article  CAS  Google Scholar 

  84. Robbins, J.B., R. Schneerson and S.C. Szu. 1995. Persepctive: Hypothesis: Serum IgG antibody is suficient to confer protection against infectious diseases by inactivating the inoclum. J. Infect. Dis. 171: in press

    Google Scholar 

  85. Robbins JB, Schneerson R, Glode MP, Vann WF, Schiffer MS, Liu T-Y, Parke JC Jr. Huntley C. Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria. J. All. Clin. Immunol. 1975:56:141–51.

    Article  CAS  Google Scholar 

  86. Robbins JB, Schneerson R. Polysaccharide-protein conjugates: A new generation of vaccines. J. Infect. Dis. 1990:161:821–32.

    Article  PubMed  CAS  Google Scholar 

  87. Robbins JB. Towards a new vaccine for pertussis. In: Schlesinger, J., ed., Microbiology. Washington, DC: American Society for Microbiology, 1994:176–83.

    Google Scholar 

  88. Robbins JD, Robbins JB. Re-examination of the immunopathogenic role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J. Infect. Dis. 1984: 47:436–99.

    Article  Google Scholar 

  89. Salk D. Herd effect and virus eradication with use of killed poliovirus vaccine. Eds. W. van Henessenn. Develop. Biol. Stand. 1981:47:247-55.

    Google Scholar 

  90. Sato H, Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigen, pertussis toxin and filamentous hemagglutinin with mouse protective activity in an intracerebral or aerosol challenge system. Infect. Immun. 1984:46:415–21.

    PubMed  CAS  Google Scholar 

  91. Sato Y, Ito A, Chiba J, Sato Y. Monoclonal antibody against pertussis toxin: Effect on toxin activity and pertussis infection. Infect. Immun. 1994:46:422–28.

    Google Scholar 

  92. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 1980:152:361–76.

    Article  PubMed  CAS  Google Scholar 

  93. Sellwood R, Hall G, Anger H. et al. Emigration of polymorphonuclear leucocytes in to the intestinal lumen of the neonatal piglet in response to challenge with K88-positive Escherichia coli. Res. Veter. Sci. 1986:40:128–35.

    CAS  Google Scholar 

  94. Shurin PA, Rehmus JM, Johnson CE. et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J. Pediatr. 1993:123:801–10.

    Article  PubMed  CAS  Google Scholar 

  95. Smith DH, Peter G, Ingram DL, Anderson P. Responses of children immunized with the capsular polysaccharide of Haemophilus influenzae type b. Pediatrics. 1975:52:637–41.

    Google Scholar 

  96. Springer GF, Horton RE, Forbes M. et al. Origin of anti-human blood group B agglutinins in white leghorn chicks. J. Exp. Med. 1959:110:221–44.

    Article  PubMed  CAS  Google Scholar 

  97. Sutter RW, PA Patriarca. Inactivated and live atttenuated poliovirus vaccines: mucosal immunity. In: Kurstak E. ed. Measles and poliomyelitis. Vaccines and immunisation. New York: Springer Verlag, 1993.

    Google Scholar 

  98. Syndman DR, Werner BG, Heinze-Lacey B. et al. Use of cytomegalovirus globulin to prevent cytomegalovirus disease in renal tranplant recipients. N. Eng. J. Med. 1987:317:1049–54.

    Article  Google Scholar 

  99. Szu SC, Gupta RK, Robbins JB. Induction of serum vibriocidal antibodies by O-specific polysaccharideprotein conjugate vaccines for prevention of cholera. In Vibrio cholerae and Cholera. Molecular to Global Perspectives. Eds, Wachsmuth IK, Blake PA, Olsvik O. Washington, DC: American Society for Microbiology. 1994:381–94.

    Google Scholar 

  100. Szu SC, Taylor DN, Trofa AC, et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines Infect. Immun. in press. 1994.

    Google Scholar 

  101. Takala AK, Eskola J, Leinonen M., Kayhty H, Nissinen A, Pekkanen E, Makela PH. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J. Infect. Dis. 1991:164:982–5

    Article  PubMed  CAS  Google Scholar 

  102. Taylor DN, Trofa AC, Sadoff J, Chu C., Bryla D, Shiloach J, Cohen D, Ashkenazi S, Lerman Y, Egan W, Schneerson R, Robbins JB. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a and Shigella sonnei (Plesiomonas shigelloides) bound to bacteria toxoids. Infect. Immun. 1994:61:3678–87.

    Google Scholar 

  103. Trollfors, B., J. Taranger, T. Lagergard, L. Lind, V Sundh, G. Zackrisson, W Blackwelder, C.U. Lowe and J. B. Robbins. 194. A double-blind, placebo-controlled trial of a monocomponent pertussis toxoid vaccine. Submitted for publication

    Google Scholar 

  104. Vann WF, Liu T-Y, Robbins JB. et al. Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect. Immun. 1976:13:1654–62.

    PubMed  CAS  Google Scholar 

  105. van Wezel AL, van Steenis G, Hannik CA, Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev. Biol. Stand. 1978:41:159–168.

    PubMed  Google Scholar 

  106. Vialard J, LaLumiere M., Vernet T. et al. Synthesis of the membrane fusion and hemagglutinin proteins of measles virus, using a novel baculovirus vector containing the β-galactosidase gene. J Virol. 1990:64:37–50.

    PubMed  CAS  Google Scholar 

  107. Wagner DK, Clements ML, Reimer CB, Synder M., Nelson DL, Murphy BR. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J. Clin. Microbiol. 1987:25:559–62.

    PubMed  CAS  Google Scholar 

  108. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog. Allergy. Karger S, Basel, 1969:13:1–110.

    CAS  Google Scholar 

  109. Watson DC, Robbins JB, and Szu SC, et al. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein vaccine. Infect. Immun. 1992:60:4679–86.

    PubMed  CAS  Google Scholar 

  110. Weibel RE, Buynak EB, McLean AA, Roehm RR, Hilleman MR. Persistence of antibody in human subjects 7 to 10 years following administration of combined live attenuated measles, mumps and rubella virus vaccines. Proc. Soc. Exp. Biol. Med. 1980:165:260–3.

    PubMed  CAS  Google Scholar 

  111. Wernet P, Breu H, Knop J, Rowley D. Antibacterial action of specific IgA and transport of IgM, IgA and IgG from serum into the small intestine. J. Infect. Dis. 1971:124:223–6.

    Article  PubMed  CAS  Google Scholar 

  112. Werzberger A, Mensch B, Kuter B. et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Eng J Med. 1993:327:453–7.

    Article  Google Scholar 

  113. Wong KH, Barrera O, Sutton A. et al. Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J. Biol. Stand. 1977:5:197–215.

    Article  PubMed  CAS  Google Scholar 

  114. World Health Organization Expert Committee on Biologic Standardization. Technical Report Series 840, 43rd Ed Geneva, Switzerland. Requirements on Vi polysaccharide for typhoid. 1993:14-32.

    Google Scholar 

  115. World Health Organization. Requirements for Haemophilus type b conjugate vaccines. WHO Technical Report Series, 1991:814.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, 20892, USA

    John B. Robbins, Rachel Schneerson & Shousun C. Szu

Authors
  1. John B. Robbins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel Schneerson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shousun C. Szu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Israel Institute for Biological Research, Ness-Ziona, Israel

    Sara Cohen  & Avigdor Shafferman  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media New York

About this chapter

Cite this chapter

Robbins, J.B., Schneerson, R., Szu, S.C. (1996). Hypothesis: How Licensed Vaccines Confer Protective Immunity. In: Cohen, S., Shafferman, A. (eds) Novel Strategies in the Design and Production of Vaccines. Advances in Experimental Medicine and Biology, vol 397. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1382-1_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-1382-1_22

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-1384-5

  • Online ISBN: 978-1-4899-1382-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation